DIPYRIDAMOLE SUMMARY
Dipyridamole USP
25 mg, 50 mg, and 75 mg tablets
Dipyridamole is a coronary vasodilator described as 2,6 bis-(diethanolamino)-4,8 dipiperidino-pyrimido-(5,4-d) pyrimidine.
Dipyridamole Injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately.
In a study of about 1100 patients who underwent coronary arteriography and Dipyridamole Injection assisted thallium imaging, the results of both tests were interpreted blindly and the sensitivity and specificity of the dipyridamole thallium study in predicting the angiographic outcome were calculated. The sensitivity of the dipyridamole test (true positive dipyridamole divided by the total number of patients with positive angiography) was about 85%. The specificity (true negative divided by the number of patients with negative angiograms) was about 50%.
In a subset of patients who had exercise thallium imaging as well as dipyridamole thallium imaging, sensitivity and specificity of the two tests were almost identical.
|
NEWS HIGHLIGHTS
Published Studies Related to Dipyridamole
Effect of dipyridamole plus aspirin on hemodialysis graft patency. [2009.05.21]
BACKGROUND: Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity... CONCLUSIONS: Treatment with dipyridamole plus aspirin had a significant but modest effect in reducing the risk of stenosis and improving the duration of primary unassisted patency of newly created grafts. (ClinicalTrials.gov number, NCT00067119.) 2009 Massachusetts Medical Society
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. [2008.09.18]
BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel... CONCLUSIONS: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.) 2008 Massachusetts Medical Society
A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. [2008.08]
CONCLUSION: Allopurinol is clinically effective and well-tolerated adjunctively with lithium in manic episodes and may represent an alternative approach in the treatment of acute mania, especially for those presenting tolerability and safety issues with antipsychotics. The present results strongly support the involvement of the purinergic system in the pathophysiology and therapeutics of bipolar disorder. Further placebo-controlled studies with allo-purinol compared with standard mood stabilizers in mania and maintenance are warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00560079.
A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole Adjunctive to Lithium in Acute Bipolar Mania. [2008.07.29]
CONCLUSION: Allopurinol is clinically effective and well-tolerated adjunctively with lithium in manic episodes and may represent an alternative approach in the treatment of acute mania, especially for those presenting tolerability and safety issues with antipsychotics. The present results strongly support the involvement of the purinergic system in the pathophysiology and therapeutics of bipolar disorder. Further placebo-controlled studies with allopurinol compared with standard mood stabilizers in mania and maintenance are warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00560079.
Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. [2008.04]
Chronic urticaria (CU) imposes profound impairment on patient's quality of life. Our study was done to evaluate the clinical efficacy and safety of desloratadine combined with dipyridamole, which is a platelet adhesion inhibitor in the treatment of CU... These findings provide new insights into the pathogenesis of CU and suggest new therapeutic opportunities for treating this disease.
Clinical Trials Related to Dipyridamole
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? [Completed]
This study is performed to determine whether a seven day treatment with dipyridamole (slow
release, 200mg twice daily) can induce a protective effect against ischemia-reperfusion
injury, after ischemic exercise of the non-dominant forearm in healthy volunteers.
Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? [Completed]
The purpose of this project is to explore the interaction between caffeine and dipyridamole
on ischemia-reperfusion injury in the forearm.
Dipyridamole/Magnesium To Improve Sickle Cell Hydration [Terminated]
The purpose of this study is to determine the benefits as well as side effects of giving
drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA).
Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer [Active, not recruiting]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Dipyridamole may increase the effectiveness of methotrexate and
kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining methotrexate and dipyridamole
in treating patients with advanced ovarian cancer that is recurrent after or refractory to
cisplatin-based chemotherapy.
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) [Recruiting]
This research study will evaluate the effects of aspirin and dipyridamole alone and in
combination on the blood flow in the vessels of the legs. We will examine how these
medications are able to inhibit the clotting of platelets in the vessels of patients with
PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that
have the ability to adhere to each other to form clots.
|
